Clinical Pharmacology of Recombinant Human Erythropoietin (r‐HuEPO)

10.1016/S0272-6386(88)80150-1

10.1056/NEJM198701083160203

10.1016/S0140-6736(86)92192-6

10.1038/ki.1985.109

10.1016/S0171-2985(86)80101-2

10.1101/SQB.1986.051.01.082

10.1021/bi00383a034

Fukuda M., 1989, Erythropoietin metabolism and the influence of carbohydrate structure, Contrib Nephrol, 76, 78, 10.1159/000417883

10.1016/S0021-9258(18)45317-3

10.1172/JCI113363

Koury ST, 1988, Localization of erythropoietin synthesis in the murine kidneys by in situ hybridization, Blood, 71, 524, 10.1182/blood.V71.2.524.524

Fried W., 1973, The liver as a source of extrarenal erythropoietin production, Blood, 40, 671, 10.1182/blood.V40.5.671.671

Vogt CH, 1989, A role for the macrophage in normal hemopoiesis. III. In vitro and in vivo erythropoietin gene expression in macrophages detected by in situ hybridization, Exp Hematol, 17, 391

10.1182/blood.V8.4.349.349

10.1159/000416003

Erslev AJ, 1980, Plasma erythropoietin in health and disease, Ann Clin Lab Sci, 10, 250

10.1007/978-1-4612-6301-2

Golde DW, 1985, Hematopoietic stem cells

10.3109/00365518709168952

10.1007/BF00627926

10.1111/j.1600-0609.1982.tb00578.x

10.1159/000417885

10.1038/clpt.1990.76

10.1159/000417887

10.1111/j.1365-2141.1981.tb07215.x

10.1111/j.1365-2265.1982.tb01608.x

Flaharty K., 1990, Pharmacokinetics of human recombinant erythropoietin in ESRD patients [abstr], Kidney Int, 37, 237

Bommer J., 1990, Efficacy of intravenous (IV) and subcutaneous (SC) recombinant human erythropoietin (r‐HuEPO) therapy in hemodialysis patients (abstr), Kidney Int, 37, 289

Boelaert J., 1988, Recombinant human erythropoietin pharmacokinetics in CAPD patients: comparison of the intravenous, subcutaneous, and intraperitoneal routes [letter], Nephrol Dial Transplant, 3, 493

10.1016/S0140-6736(89)92832-8

10.1159/000417886

10.1159/000417889

Krömer G., 1990, Single‐dose pharmacokinetics of recombinant human erythropoietin (r‐HuEPO) comparing intravenous (IV) and subcutaneous (SC) and intraperitoneal (IP) administration in IPD patients [abstr], Kidney Int, 37, 331

10.1159/000417888

Besarab A., 1990, Subcutaneous (sc) administration of recombinant human erythropoietin (r‐HuEPO) for treatment of anemia in ESRD [abstr], Kidney Int, 37, 236

10.1016/S0140-6736(88)90975-0

10.1182/blood.V73.1.90.90

Salmonson T., 1990, Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure, Kidney Int

10.7326/0003-4819-110-2-108

Egrie JC, 1988, Pharmacokinetics of recombinant human erythropoietin (r‐HuEPO) administered to hemodialysis patients [abstr], Kidney Int, 33, 262A

Amgen Inc.Epogen package insert. Thousand Oaks CA;1989 June.

10.1093/oxfordjournals.ndt.a091888

Miller CB, 1989, Decreased erythropoietin (EPO) response associated with the anemia of malignancy [abstr], Proc Am Soc Clin Oncol, 8, 182

10.1056/NEJM198910263211705